Essential cancer medicines: adding feasibility to the magnitude of clinical benefit value chain

CONCLUSION: Due to the rising costs associated with newly available therapies, structured, reproducible, and field-tested tools to evaluate the added clinical benefit from these therapies need to be implemented in pre-selecting potential candidate medicines to be included in the WHO EML. ESMO is proud to collaborate closely with WHO on this important global public health initiative.PMID:37672862 | DOI:10.1016/j.esmoop.2023.101617

Source: Cancer Control - September 6, 2023 Category: Cancer & Oncology Authors: F Roitberg T Amaral N I Cherny R Giuliani N J Latino M Galotti G Bricalli G Curigliano G Pentheroudakis D Trapani Source Type: research